Clinical Trial Update: RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode [Phase 2]

View source ↗

Summary

Phase 2 trial RESIST evaluating MAP4343 in antidepressant non-responders with a major depressive episode has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• MAP4343

Snippet

Sponsor: Mapreg | Conditions: Depression | Phase 2 | Status: COMPLETED